Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings

Ophthalmology

Volumn 125, Issue 10, 2018, Pages 1608-1622

  Wong, Tien Y ^a,b   Sun, Jennifer ^c   Kawasaki, Ryo ^d   Ruamviboonsuk, Paisan ^e   Gupta, Neeru ^f   Lansingh, Van Charles ^g   Maia, Mauricio ^h   Mathenge, Wanjiku ⁱ   Moreker, Sunil ^j   Muqit, Mahi M K ^k   Resnikoff, Serge ^l   Verdaguer, Juan ^m   Zhao, Peiquan ⁿ   Ferris, Frederick ^o   Aiello, Lloyd P ^c   Taylor, Hugh R ^p  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YAMAGATA UNIVERSITY   (Japan)

^e RAJAVITHI HOSPITAL   (Thailand)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g University of Tennessee Health Science Center   (Mexico)

^h FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ Rwanda International Institute of Ophthalmology Dr Agarwal's Eye Hospital   (Rwanda)

^j MGM Hospital   (India)

^k MOORFIELDS EYE HOSPITAL   (United Kingdom)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m UNIVERSIDAD DE LOS ANDES   (Chile)

ⁿ XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^o NATIONAL EYE INSTITUTE   (United States)

^p UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; STEROID; VASCULOTROPIN INHIBITOR;

CATARACT; CATARACT EXTRACTION; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; EYE CARE; FOLLOW UP; HUMAN; PATIENT REFERRAL; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; REVIEW; SCREENING; DISEASE MANAGEMENT; GLOBAL HEALTH; MEDICAL SOCIETY; MORBIDITY; OPHTHALMOLOGY; STANDARDS; TRENDS; VISION TEST;

DIABETIC RETINOPATHY; DISEASE MANAGEMENT; FOLLOW-UP STUDIES; GLOBAL HEALTH; HUMANS; MORBIDITY; OPHTHALMOLOGY; PRACTICE GUIDELINES AS TOPIC; REFERRAL AND CONSULTATION; SOCIETIES, MEDICAL; VISION SCREENING;

EID: 85047222654     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2018.04.007     Document Type: Review

References (86)

1. Chan, J.C., Malik, V., Jia, W., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:20 (2009), 2129–2140.
2. Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:1 (2010), 4–14.
3. Werfalli, M., Engel, M.E., Musekiwa, A., et al. The prevalence of type 2 diabetes among older people in Africa: a systematic review. Lancet Diabetes Endocrinol 4:1 (2016), 72–84.
4. Yoon, K.H., Lee, J.H., Kim, J.W., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 368:9548 (2006), 1681–1688.
5. Sattar, N., Gill, J.M., Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. Lancet Diabetes Endocrinol 3:12 (2015), 1004–1016.
6. Leasher, J.L., Bourne, R.R., Flaxman, S.R., et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care 39:9 (2016), 1643–1649.
7. International Diabetes Foundation. Diabetes: facts and figures. http://www.idf.org/about-diabetes/facts-figures Accessed December 1, 2017.
8. Abegunde, D.O., Mathers, C.D., Adam, T., et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370:9603 (2007), 1929–1938.
9. Beran, D., Yudkin, J.S., Diabetes care in sub-Saharan Africa. Lancet 368:9548 (2006), 1689–1695.
10. Mbanya, J.C., Motala, A.A., Sobngwi, E., et al. Diabetes in sub-Saharan Africa. Lancet 375:9733 (2010), 2254–2266.
11. Tan, G.S., Cheung, N., Simo, R., et al. Diabetic macular oedema. Lancet Diabetes Endocrinol 5:2 (2017), 143–155.
12. Wong, T.Y., Klein, R., Islam, F.M., et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 141:3 (2006), 446–455.
13. Zhang, X., Saaddine, J.B., Chou, C.F., et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 304:6 (2010), 649–656.
14. Yau, J.W., Rogers, S.L., Kawasaki, R., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:3 (2012), 556–564.
15. Mathenge, W., Bastawrous, A., Peto, T., et al. Prevalence and correlates of diabetic retinopathy in a population-based survey of older people in Nakuru, Kenya. Ophthal Epidemiol 21:3 (2014), 169–177.
16. Beagley, J., Guariguata, L., Weil, C., Motala, A.A., Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 103:2 (2014), 150–160.
17. Zhang, X., Geiss, L.S., Cheng, Y.J., et al. The missed patient with diabetes: how access to health care affects the detection of diabetes. Diabetes Care 31:9 (2008), 1748–1753.
18. Gakidou, E., Mallinger, L., Abbott-Klafter, J., et al. Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys. Bull World Health Organ 89:3 (2011), 172–183.
19. Bressler, N.M., Varma, R., Doan, Q.V., et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol 132:2 (2014), 168–173.
20. Ferris, F.L. 3rd, How effective are treatments for diabetic retinopathy?. JAMA 269:10 (1993), 1290–1291.
21. Cheung, N., Mitchell, P., Wong, T.Y., Diabetic retinopathy. Lancet 376:9735 (2010), 124–136.
22. Antonetti, D.A., Klein, R., Gardner, T.W., Diabetic retinopathy. N Engl J Med 366:13 (2012), 1227–1239.
23. Klein, R., Knudtson, M.D., Lee, K.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 116:3 (2009), 497–503.
24. Ting, D.S., Cheung, G.C., Wong, T.Y., Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol 44:4 (2016), 260–277.
25. Wong, T.Y., Mwamburi, M., Klein, R., et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 32:12 (2009), 2307–2313.
26. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:14 (1993), 977–986.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:9131 (1998), 837–853.
28. Fong, D.S., Aiello, L.P., Ferris, F.L. 3rd, Klein, R., Diabetic retinopathy. Diabetes Care 27:10 (2004), 2540–2553.
29. Javitt, J.C., Aiello, L.P., Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124:1 Pt 2 (1996), 164–169.
30. Rohan, T.E., Frost, C.D., Wald, N.J., Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. BMJ 299:6709 (1989), 1198–1201.
31. Resnikoff, S., Felch, W., Gauthier, T.M., Spivey, B., The number of ophthalmologists in practice and training worldwide: a growing gap despite more than 200,000 practitioners. Br J Ophthalmol 96:6 (2012), 783–787.
32. Burgess, P.I., Msukwa, G., Beare, N.A., Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic. BMC Med, 11, 2013, 157.
33. World Health Organization. WHO model list of essential medicines. http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 Accessed December 1, 2017.
34. Hooper, P., Boucher, M.C., Colleaux, K., et al. Contemporary management of diabetic retinopathy in Canada: from guidelines to algorithm guidance. Ophthalmologica 231:1 (2014), 2–15.
35. Mohamed, Q., Gillies, M.C., Wong, T.Y., Management of diabetic retinopathy: a systematic review. JAMA 298:8 (2007), 902–916.
36. Solomon, S.D., Chew, E., Duh, E.J., et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care 40:3 (2017), 412–418.
37. Bandello, F., Midena, E., Menchini, U., Lanzetta, P., Recommendations for the appropriate management of diabetic macular edema: light on DME survey and consensus document by an expert panel. Eur J Ophthalmol 26:3 (2016), 252–261.
38. Das, T., Aurora, A., Chhablani, J., et al. Evidence-based review of diabetic macular edema management: consensus statement on Indian treatment guidelines. Indian J Ophthalmol 64:1 (2016), 14–25.
39. Mitchell, P., Wong, T.Y., Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol 157:3 (2014), 505–513.e501–e508.
40. Rajavi, Z., Safi, S., Javadi, M.A., et al. Diabetic retinopathy clinical practice guidelines: customized for Iranian population. J Ophthalmic Vis Res 11:4 (2016), 394–414.
41. Ziemssen, F., Lemmen, K., Bertram, B., et al. National guidelines for treatment of diabetic retinopathy: second edition of the national guidelines for treatment of diabetic retinopathy. Ophthalmologe 113:7 (2016), 623–638.
42. Wang, L.Z., Cheung, C.Y., Tapp, R.J., et al. Availability and variability in guidelines on diabetic retinopathy screening in Asian countries. Br J Ophthalmol 101:10 (2017), 1352–1360.
43. Institute of Medicine (US) Committee on Cancer Control in Low- and Middle-Income Countries. Sloan, F.A., Gelband, H., (eds.) Cancer Control Opportunities in Low- and Middle-Income Countries, 2007, National Academies Press (US), Washington (DC) ISBN-13: 978-0-309-10384-8ISBN-10: 0-309-10384-3.
44. Owolabi, M., Miranda, J.J., Yaria, J., Ovbiagele, B., Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism. BMJ Global Health, 1(3), 2016 pii: e000105. eCollection 2016.
45. Yip, C.H., Anderson, B.O., The Breast Health Global Initiative: clinical practice guidelines for management of breast cancer in low- and middle-income countries. Expert Rev Anticancer Ther 7:8 (2007), 1095–1104.
46. International Council of Ophthalmology. ICO guidelines for diabetic eye care. http://www.icoph.org/downloads/ICOGuidelinesforDiabeticEyeCare.pdf Accessed December 1, 2017.
47. International Council of Ophthalmology. ICO guidelines for diabetic eye care: available in English, Chinese, French, Portuguese, Serbian, Spanish, and Vietnamese. http://www.icoph.org/resources/309/ICO-Guidelines-for-Diabetic-Eye-Care-available-in-English-Chinese-French-Portuguese-Serbian-Spanish-and-Vietnamese.html Accessed December 1, 2017.
48. Martinez-Zapata, M.J., Marti-Carvajal, A.J., Sola, I., et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev(11), 2014, CD008721.
49. Mohamed, Q.A., Fletcher, E.C., Buckle, M., Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema. BMJ Clin Evid, 2016;Mar 16 pii: 0702; PubMed PMID: 27031563; PubMed Central PMCID: PMC4817243.
50. International Council of Ophthalmology. ICO diabetic eye care. http://www.icoph.org/enhancing_eyecare/diabetic_eyecare.html Accessed December 1, 2017.
51. World Health Organization. Health statistics and information systems. http://www.who.int/healthinfo/global_burden_disease/definition_regions/en/ Accessed December 1, 2017.
52. Sabanayagam, C., Yip, W., Ting, D.S., et al. Ten emerging trends in the epidemiology of diabetic retinopathy. Ophthal Epidemiol 23:4 (2016), 209–222.
53. Wilkinson, C.P., Ferris, F.L. 3rd, Klein, R.E., et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:9 (2003), 1677–1682.
54. Bragge, P., Gruen, R.L., Chau, M., et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol 129:4 (2011), 435–444.
55. Horton, M.B., Silva, P.S., Cavallerano, J.D., Aiello, L.P., Operational components of telemedicine programs for diabetic retinopathy. Curr Diabetes Rep, 16(12), 2016, 128.
56. Horton, M.B., Silva, P.S., Cavallerano, J.D., Aiello, L.P., Clinical components of telemedicine programs for diabetic retinopathy. Curr Diabetes Rep, 16(12), 2016, 129.
57. Jones, S., Edwards, R.T., Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 27:3 (2010), 249–256.
58. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 88:7 (1981), 583–600.
59. Bressler, N.M., Beck, R.W., Ferris, F.L. 3rd, Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med 365:16 (2011), 1520–1526.
60. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross, J.G., Glassman, A.R., et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:20 (2015), 2137–2146.
61. Sivaprasad, S., Prevost, A.T., Vasconcelos, J.C., et al. Clinical Efficacy of Intravitreal Aflibercept versus Panretinal Photocoagulation for Best Corrected Visual Acuity in Patients with Proliferative Diabetic Retinopathy at 52 Weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 389:10085 (2017), 2193–2203.
62. Muqit, M.M., Marcellino, G.R., Henson, D.B., et al. Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study report 4. Eye 25:11 (2011), 1447–1456.
63. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 103:12 (1985), 1796–1806.
64. Relhan, N., Flynn, H.W. Jr., The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema. Curr Opin Ophthalmol 28:3 (2017), 205–212.
65. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong, D.S., Strauber, S.F., et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 125:4 (2007), 469–480.
66. Morrison, J.L., Hodgson, L.A., Lim, L.L., Al-Qureshi, S., Diabetic retinopathy in pregnancy: a review. Clin Exp Ophthalmol 44:4 (2016), 321–334.
67. Haddad, N.M., Sun, J.K., Abujaber, S., et al. Cataract surgery and its complications in diabetic patients. Semin Ophthalmol 29:5–6 (2014), 329–337.
68. Shah, A.S., Chen, S.H., Cataract surgery and diabetes. Curr Opin Ophthalmol 21:1 (2010), 4–9.
69. Scanlon, P.H., The English national screening programme for sight-threatening diabetic retinopathy. J Med Screening 15:1 (2008), 1–4.
70. Goh, J.K., Cheung, C.Y., Sim, S.S., et al. Retinal imaging techniques for diabetic retinopathy screening. J Diabetes Sci Technol 10:2 (2016), 282–294.
71. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin, J.M., et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:6 (2000), 381–389.
72. Diabetic Retinopathy Clinical Research Network, Wells, J.A., Glassman, A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:13 (2015), 1193–1203.
73. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:15 (2008), 1577–1589.
74. Cunha-Vaz, J., Ashton, P., Iezzi, R., et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 121:10 (2014), 1892–1903.
75. Augustin, A.J., Kuppermann, B.D., Lanzetta, P., et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol, 15, 2015, 150.
76. Spaide, R.F., Klancnik, J.M. Jr., Cooney, M.J., Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 133:1 (2015), 45–50.
77. Kim, A.Y., Chu, Z., Shahidzadeh, A., et al. Quantifying microvascular density and morphology in diabetic retinopathy using spectral-domain optical coherence tomography angiography. Invest Ophthalmol Vis Sci 57:9 (2016), OCT362–OCT370.
78. Durbin, M.K., An, L., Shemonski, N.D., et al. Quantification of retinal microvascular density in optical coherence tomographic angiography images in diabetic retinopathy. JAMA Ophthalmol 135:4 (2017), 370–376.
79. Bradley, P.D., Sim, D.A., Keane, P.A., et al. The evaluation of diabetic macular ischemia using optical coherence tomography angiography. Invest Ophthalmol Vis Sci 57:2 (2016), 626–631.
80. Samara, W.A., Shahlaee, A., Adam, M.K., et al. Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. Ophthalmology 124:2 (2017), 235–244.
81. Ting, D.S.W., Tan, G.S.W., Agrawal, R., et al. Optical coherence tomographic angiography in type 2 diabetes and diabetic retinopathy. JAMA Ophthalmol 135:4 (2017), 306–312.
82. Gulshan, V., Peng, L., Coram, M., et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA 316:22 (2016), 2402–2410.
83. Wong, T.Y., Bressler, N.M., Artificial intelligence with deep learning technology looks into diabetic retinopathy screening. JAMA 316:22 (2016), 2366–2367.
84. Jani, P.D., Forbes, L., Choudhury, A., et al. Evaluation of diabetic retinal screening and factors for ophthalmology referral in a telemedicine network. JAMA Ophthalmol 135:7 (2017), 706–714.
85. Shi, L., Wu, H., Dong, J., et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol 99:6 (2015), 823–831.
86. Silva, P.S., Aiello, L.P., Telemedicine and eye examinations for diabetic retinopathy: a time to maximize real-world outcomes. JAMA Ophthalmol 133:5 (2015), 525–526.